[Skip to Content]
[Skip to Content Landing]
Views 160
Citations 0
Comment & Response
August 2018

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas

Author Affiliations
  • 1Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy
  • 2Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
JAMA Oncol. 2018;4(8):1134. doi:10.1001/jamaoncol.2018.0875

To the Editor We read with interest the article by Toulmonde and colleagues1 assessing the efficacy and safety of anti–programmed cell death protein 1 (PD-1) antibody and metronomic cyclophosphamide in patients with advanced soft-tissue sarcomas. We found the rationale of this combination approach interesting and worthy of further investigation, despite their unfavorable clinical data. The choice to measure the PD-1 ligand (PD-L1) as a possible predictive parameter of immunotherapy may partially explain their negative results. In fact, PD-1 expression is clear evidence of lymphocyte activation after recognition of immunogenic, that is, tumor, antigen. Conversely, PD-L1 level may reflect only expression of its production by the tumor or tumor-associated macrophages, which, however, can be activated also and exclusively by necrosis.

×